SANN — Santhera Pharmaceuticals Holding AG Share News
0.000.00%
Last trade - 00:00- CH₣220.90m
- CH₣220.41m
- CH₣77.19m
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million
Brief: Santhera Partners Up With Ikris Pharma Network For Distribution Of Agamree In India
Brief: Santhera: Proposes Melanie Rolli As An Independent Director
Swiss stocks - Factors to watch on February 13
Brief: Santhera: Announces Agreement With German GKV-SV On Reimbursement Amount For Agamree (Vamorolone)
Brief: Santhera Says Catherine Isted Appointed As CFO
Brief: Santhera Pharmaceuticals Says Idorsia Receives $30 Mln From R-Bridge For Agamree Royalties
Brief: Santhera Pharmaceuticals Holding: Receives Positive Recommendation From Nice For Agamree® (Vamorolone) As A Treatment For Duchenne Muscular Dystrophy
Brief: Santhera’S Shareholders Approve All Board Proposals At Today’S Annual General Meeting
Brief: Santhera Announces Launch Of Early Access Program In China For Agamree By Its Partner Sperogenix
Brief: Santhera: NDA For Vamorolone In Duchenne Muscular Dystrophy Accepted And Granted Priority Review By China's NMPA
Brief: Santhera Says It Received Approval For Agamree® (Vamorolone) As A Treatment For Duchenne Muscular Dystrophy In The UK
Brief: Santhera: Agamree (Vamorolone) Approved As Treatment For Duchenne Muscular Dystrophy In UK
Brief: Santhera: Agamree Approved In EU For Treatment Of DMD In Patients Aged 4 And Older
Brief: Santhera Pharmaceuticals: FDA Approved AgamreeFor Treatment Of Duchenne Muscular Dystrophy
US FDA approves Santhera's drug for rare muscular dystrophy (updated)